CN1032003A - 苯氧基烷基羧酸衍生物及其制备方法 - Google Patents
苯氧基烷基羧酸衍生物及其制备方法 Download PDFInfo
- Publication number
- CN1032003A CN1032003A CN88106646A CN88106646A CN1032003A CN 1032003 A CN1032003 A CN 1032003A CN 88106646 A CN88106646 A CN 88106646A CN 88106646 A CN88106646 A CN 88106646A CN 1032003 A CN1032003 A CN 1032003A
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- expression
- ethanoyl
- definition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002253 acid Substances 0.000 title claims abstract description 7
- 238000002360 preparation method Methods 0.000 title claims description 12
- -1 alkali metal salt Chemical class 0.000 claims abstract description 10
- 229910052783 alkali metal Inorganic materials 0.000 claims abstract description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 5
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 3
- 239000001257 hydrogen Substances 0.000 claims abstract description 3
- 239000000043 antiallergic agent Substances 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims description 51
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 8
- 230000000903 blocking effect Effects 0.000 claims description 6
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims 1
- 239000000470 constituent Substances 0.000 claims 1
- 125000005359 phenoxyalkyl group Chemical group 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 abstract description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 35
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 15
- HNAGHMKIPMKKBB-UHFFFAOYSA-N 1-benzylpyrrolidine-3-carboxamide Chemical compound C1C(C(=O)N)CCN1CC1=CC=CC=C1 HNAGHMKIPMKKBB-UHFFFAOYSA-N 0.000 description 9
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- OBNCKNCVKJNDBV-UHFFFAOYSA-N butanoic acid ethyl ester Natural products CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 description 9
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 8
- 150000002617 leukotrienes Chemical class 0.000 description 7
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 7
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 6
- 235000007715 potassium iodide Nutrition 0.000 description 5
- 229960004839 potassium iodide Drugs 0.000 description 5
- 206010006482 Bronchospasm Diseases 0.000 description 4
- ICMAFTSLXCXHRK-UHFFFAOYSA-N Ethyl pentanoate Chemical compound CCCCC(=O)OCC ICMAFTSLXCXHRK-UHFFFAOYSA-N 0.000 description 4
- 230000007885 bronchoconstriction Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical class O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 230000002052 anaphylactic effect Effects 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 3
- 235000015320 potassium carbonate Nutrition 0.000 description 3
- 235000017550 sodium carbonate Nutrition 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- SEXKDZSOKXPFFH-UHFFFAOYSA-N 1-(2-benzoylphenyl)ethanone Chemical compound CC(=O)C1=CC=CC=C1C(=O)C1=CC=CC=C1 SEXKDZSOKXPFFH-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- YZGQDNOIGFBYKF-UHFFFAOYSA-N Ethoxyacetic acid Chemical compound CCOCC(O)=O YZGQDNOIGFBYKF-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical class O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical class C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- LCPVQAHEFVXVKT-UHFFFAOYSA-N 2-(2,4-difluorophenoxy)pyridin-3-amine Chemical compound NC1=CC=CN=C1OC1=CC=C(F)C=C1F LCPVQAHEFVXVKT-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 1
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical class O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000002590 anti-leukotriene effect Effects 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- SLUNEGLMXGHOLY-UHFFFAOYSA-N benzene;hexane Chemical compound CCCCCC.C1=CC=CC=C1 SLUNEGLMXGHOLY-UHFFFAOYSA-N 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- GWNVDXQDILPJIG-NXOLIXFESA-N leukotriene C4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-NXOLIXFESA-N 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- CHQMHPLRPQMAMX-UHFFFAOYSA-L sodium persulfate Substances [Na+].[Na+].[O-]S(=O)(=O)OOS([O-])(=O)=O CHQMHPLRPQMAMX-UHFFFAOYSA-L 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C62/08—Saturated compounds containing ether groups, groups, groups, or groups
- C07C62/12—Saturated compounds containing ether groups, groups, groups, or groups polycyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
苯氧基烷基羧酸衍生物的一般式为:
式中的R1代表氢,甲基或乙基;m为2,3或4,
n为3或4。这些羧酸衍生物的碱金属盐和水合物
用作抗过敏剂是有用的。
Description
本发明涉及某些新颖苯氧基烷基羧酸衍生物,它们的中间体及其制备方法。这些羧酸衍生物具有强的和选择性的抗白三烯(leukotriene)作用并对预防或治疗象哮喘那样的过敏性疾病是有用的。
进一步,本发明涉及某些新颖的苯氧基烷基羧酸衍生物的一般式为:
式中R1代表氢,甲基或乙基,m为2,3或4,n为3或4,以及它们的碱金属盐和水合物。
廿碳四烯酸经5-脂肪氧合酶途经的代谢物-白三烯类[白三烯C4,D4和E4]是SRS-A(过敏性的慢反应物)的成份,是象支气管炎哮喘那样的直接类过敏性症的一个重要介质。据此,白三烯拮抗药物在治疗过敏性疾病中是有前途的。然而,所知的是只有极少具有这些作用的内服药物,且无实际应用。
现有专利(日本专利公开号58-189137,相应的美国专利4,507,498)中公开的一个混合样品中有[6-乙酰基-3-(4-乙酰基-3-羟基-2-丙基苯氧基)丙氧基]-2-丙基苯氧基]乙酸,公开的所有其他样品中有4-乙酰基-3-取代-2-丙基苯氧基乙酸,然而现有专利公开的化合物,由于它们的低药效就不能用作白三烯拮抗剂。
经努力研究白三烯拮抗剂,本发明人发现一般式(Ⅰ)的化合物通过口服时白三烯D4引起的支气管收缩具有强的选择性拮抗作用。还惊奇地发现,这些化合物在豚鼠的气道超敏感性方面显现出显著的抑制作用。
一般式(Ⅰ)所代表的化合物为;例如:4-[6-乙酰基-3-[2-(4-乙酰基-3-羟基-2-丙基一苯氧基)-乙氧基]-2-丙基苯氧基]丁酸,4-[6-乙酰基-3-[3-(4-乙酰基-3-羟基-2-丙基苯氧基)丙氧基]-2-丙基苯氧基]丁酸,4-[6-乙酰基-3-[4-(4-乙酰基-3-羟基-2-丙基苯氧基)丁氧基]-2-丙基苯氧基]丁酸,5-[6-乙酰基-3-[3-(4-乙酰基-3-羟基-2-丙基苯氧基)丙氧基]-2-丙基苯氧基]-戊酸。
按照本发明,一般式(Ⅰ)代表的化合物可以下列路线制备:
(1)一般式(Ⅰ)中R1为氢原子的化合物可通过水解一般式(Ⅰa)的化合物制备,尤其是,在搅拌下加热一般式(Ⅰa)代表的化合物与诸如氢氧化钠,氢氧化钾的碱溶液制备一般式(Ⅰ)的化合物。
式中,m和n如上所述,R2代表甲基或乙基。
(2)一般式(Ⅰa)代表的化合物可以由一般式(Ⅲ)代表的化合物与一般式(Ⅱ)代表的化合物反应而得。特别是,可以由一般式(Ⅲ)代表的化合物与一般式(Ⅱ)代表的化合物在诸如丙酮、甲基乙基酮,二乙基酮,二甲基甲酰胺等有机溶剂中,在诸如碳酸钾,碳酸钠的碱存在下反应而得,反应温度较好的是在室温与回流温度之间。更好的是加入象碘化钾之类的催化剂。
式中R2,n和m如上所述,Y代表一个离去基团。
一般式(Ⅲ)中的Y较好地是一个卤素原子,比如,氯或溴原子。
(3)一般式(Ⅰa)代表的化合物还可通过让一般式(Ⅴ)代表的化合物与一般式(Ⅳ)代表的化合物反应制得。特别是可以由一般式(Ⅴ)表示的化合物与一般式(Ⅳ)表示的化合物在诸如丙酮,甲基乙基酮,二乙基酮,二甲基酰胺等有机溶剂中,在有诸如碳酸钾,碳酸钠的碱存在下,于室温至回流温度下反应而得。更好的是加入象碘化钾之类的催化剂。
式中R2,m和n如前所述,Y表示一个离去基团。
一般式(Ⅳ)中的Y较好的是象氯或溴的卤素原子。
(4)一般式(Ⅱ)表示的化合物可以由去除一般式(Ⅷ)表示的化合物中的保护基团而制得。一般式(Ⅷ)表示的化合物可由一般式(Ⅶ)表示的化合物与一般式(Ⅵ)表示的化合物在诸如丙酮,甲基乙基酮,二乙基酮,二甲基甲酰胺的有机溶剂中,于室温至回流温度下,在诸如碳酸钾,碳酸钠的碱的存在下,更好的是在反应混合物中加入碘化钾反应而得。
一般式(Ⅵ)和(Ⅷ)中的R3是一个诸如苄基,甲氧基甲基那样的保护基团。如果保护基团是苄基,一般式(Ⅱ)表示的化合物可由用钯-碳的氢解反应制得。
式中R3表示一个保护基团。
式中,R2,n如前所述,X表示一个离去基团
式中,R2,R3和n如前所述。
一般式(Ⅶ)中的X最好是象氯或溴原子那样的卤素原子。
下面结合具体实例描述本发明,但本发明并不限于这些实例。
实例1
4-[6-乙酰基-3-[3-(4-乙酰基-3-羟基-2-丙基苯氧基)丙氧基]-2-丙基苯氧基]丁酸乙酯
1)4-(6-乙酰基-3-苄氧基-2-丙基苯氧基)丁酸乙酯
3.0克4-苄氧基-2′-羟基-3′-丙基乙酰苯酮,2.9克无水碳酸钾和0.5克碘化钾混合物在40毫升N,N-二甲基甲酰胺中,在100℃下搅拌,然后边搅拌边滴加3,1克-4-溴丁酸乙酯于混合物中,再搅拌8小时,然后该混合物倒入冰水中再用乙酸乙酯抽提,有机层经水洗后,用无水硫酸钠干燥并蒸干。所得残留物用20∶1的苯/乙酸乙酯洗提的硅胶柱色谱提纯,得到2.2克棕褐色油状的本标题名称化合物,产率52.3%。
H1-核磁共振谱(CDCl3)
δ:0.98(3H,t,J=7Hz,-CH2CH2CH3),1.27(3H,t,J=7Hz,COOCH2CH3),1.60(2H,m,CH2CH2CH3),2.14(2H,m,OCH2CH2COOEt),2.50(2H,t,J=6Hz,CH2COOEt),2.58(3H,s,COCH3),2.66(2H,t,J=7Hz,CH2CH2CH3),3.81(2H,t,J=6Hz,OCH2CH2CH2COOEt),4.15(2H,q,J=7Hz,COOCH2CH3),5.11(2H,s,phCH2),6.71(1H,d,J=9Hz, ),7.38(5H,m,ph),7.51(1H,d,J=9Hz, ).
2)4-(6-乙酰基-3-羟基-2-丙基苯氧基)丁酸乙酯
含有2.2克4-(6-乙酰基-3-苄氧基-2-丙基苯氧基)丁酸乙酯的30毫升乙醇溶液在室温常压下经载有10%的钯的0.45克活性碳氢化,在吸氢反应停止后,去除催化剂,蒸发溶液。残留物经1∶4的苯/乙酸乙酯洗脱的硅胶柱色谱精制提纯,给出1.2g黄色油状的本标题名称化合物,产率70.5%。
H1-核磁共振谱(CDCl3)
δ:0.98(3H,t,J=7Hz,-CH2CH2CH3),1.27(3H,t,J=7Hz,COOCH2CH3),1.54(2H,m,CH2CH2CH3),2.14(2H,m,OCH2CH2CH2COOEt),2.51(2H,m,CH2COOEt),2.58(3H,s,COCH3),2.60(2H,m,CH2CH2CH3),3.80(2H,t,J=6Hz,OCH2CH2CH2COOEt),4.16(2H,q,J=7Hz,COOCH2CH3),6.62(1H,d,J=9Hz, ),7.43(1H,d,J=9Hz, ).
3)4-[6-乙酰基-3-[3-(4-乙酰基-3-羟基-2-丙基苯氧基-丙氧基]-2-丙基苯氧基]丁酸乙酯
4′-(3-溴丙氧基)-2′-羟基-3′-丙基乙酰苯酮(1.35克)的丙酮(10毫升)溶液在搅拌下滴加入4-(6-乙酰基-3-羟基-2-丙基苯氧基)丁酸乙酯(1.2克),无水磺酸钠(0.7克)及碘化钾(0.5克)在丙酮(50毫升)中组成的回流混合液中,5小时后,再加入0.5克无水碳酸钾,接着回流该化合物13小时,然后过滤混合物,蒸发溶剂,所得残留物用4∶1的苯/乙酸乙酯洗脱硅胶柱色谱提纯,得到1.7克溶点为77-79℃的无色晶体状的本标题名称的化合物,产率80.5%。
分析(%)C31H42O8,其计算值(实测值)为:
C,68.61(68.66);H,7.80(7.75)
实例2
5-[6-乙酰基-3-[3-(4-乙酰基-3-羟基-2-丙基苯氧基)丙氧基]-2-丙基苯氧基]戊酸乙酯
1)5-(6-乙酰基-3-苄氧基-2-丙基苯氧基)戊酸乙酯,这个化合物的制备方法与实例1-1)相同,所得产物呈棕褐色油状,产率为39.2%
H1-核磁共振谱(CDCl3)
δ:0.98(3H,t,J=7Hz,-CH2CH2CH3),1.26(3H,t,J=7Hz,COOCH2CH3),1.56(2H,m,CH2CH2CH3),1.85(4H,m,OCH2CH2CH2CH2COOEt),2.40(2H,m,CH2COOEt),2.58(3H,s,COCH3),2.69(2H,m,CH2CH2CH3),3.77(2H,m,OCH2(CH2)3COOEt),4.13(2H,q,J=7Hz,COOCH2CH3),5.10(2H,s,PhCH2),6.70(1H,d,J=9Hz, ),7.37(5H,m,Ph),7.50(1H,d,J=9Hz, ).
2)5-(6-乙酰基-3-苄氧基-2-丙基苯氧基)戊酸乙酯
这个化合物的制备方法与实例1-2)相同,所得产物呈棕褐色油状,产率为97.1%。
H1-核磁共振谱(CDCl3)
δ:0.98(3H,t,J=7Hz,-CH2CH2CH3),1.23(3H,t,J=7Hz,COOCH2CH3),1.54(2H,m,CH2CH2CH3),1.85(4H,m,OCH2CH2CH2CH2COOEt),2.30(2H,m,CH2COOEt),2.59(3H,s,COCH3),2.60(2H,m,CH2CH2CH3),3.77(2H,m,OCH2(CH2)3COOEt),4.15(2H,q,J=7Hz,COOCH2CH3),6.63(1H,d,J=9Hz, ),7.42(1H,d,J=9Hz, ).
3)5-[6-乙酰基-3-[3-(4-乙酰基-3-羟基-2-丙基苯氧基)-丙氧基-2-丙基苯氧基]戊酸乙酯
这个化合物的制备方法与实例1-3)相同,所得产物呈黄色油状,产率为57.9%。
H1-核磁共振谱(CDCl3)
δ:0.90(3H,t,J=7Hz,-CH2CH2CH3),0.94(3H,t,J=7Hz,-CH2CH2CH3),1.26(3H,t,J=7Hz,COOCH2CH3),1.52(4H,m,CH2CH2CH3×2),1.83(4H,m,OCH2CH2CH2CH2COOEt),2.36(4H,m,CH2COOEt,OCH2CH2CH2O),2.50(2H,m,CH2CH2CH3),2.56(3H,s,COCH3),2.57(3H,s,COCH3),2.60(2H,m,CH2CH2CH3),3.75(2H,m,OCH2(CH2)3COOEt),4.13(2H,q,J=7Hz,COOCH2CH3),4.24(4H,m,OCH2CH2CH2O),6.45 and 6.67(1H,d,J=9Hz, ),7.51 and 7.58(1H,d,J=9Hz, ),12.72(1H,s,OH).
实例3
4-[6-乙酰基-3-[2-(4-乙酰基-3-羟基-2-丙基苯氧基)乙氧基]-2-丙基苯氧基]丁酸乙酯
本标题化合物可按实例1-3)相同方法制得,所得产物呈褐色油状,产率52.5%。
实例4
4-[6-乙酰基-3-[4-(4-乙酰基-3-羟基-2-丙基苯氧基)丁氧基]-2-丙基苯氧基]丁酸乙酯
本标题化合物的制备方法与实例1-3)相同,所得产物呈褐色油状,为60.9%。
H1-核磁共振谱(CDCl3)
δ:0.93 and 0.97(3H,t,J=7Hz,-CH2CH2CH3),1.27(3H,t,J=7Hz,COOCH2CH3),1.56(4H,m,CH2CH2CH3×2),2.04(4H,m,OCH2CH2CH2CH2O),2.14(2H,m,OCH2CH2CH2COOEt),2.51(4H,m,CH2COOEt,CH2CH2CH3),2.56 and 2.58(3H,s,COCH3),2.65(2H,m,CH2CH2CH3),3.80(2H,t,J=6Hz,OCH2CH2CH2COOEt),4.10(4H,m,OCH2CH2CH2CH2O),4.16(2H,q,J=7Hz,COOCH2CH3),6.44 and 6.66(1H,d,J=9Hz, ),7.53 and 7.58(1H,d,J=9Hz, ),12.74(1H,s,OH).
实例5
4-[6-乙酰基-3-[3-(4-乙酰基-3-羟基-2-丙基苯氧基)丙氧基]-2-丙基苯氧基]丁酸
1.7克实例1的4-[6-乙酰基-3-[3-(4-乙酰基-3-羟基-2-丙基苯氧基)丙氧基]-2-丙基苯氧基]丁酸乙酯与5毫升乙醇组成的溶液中加入含0.38克氢氧化钠的5毫升水的溶液,在水浴上加热10分钟,倒入冰水中,用浓盐酸酸化,再用乙酸乙酯抽提。水洗有机层,经克水硫酸钠干燥,再蒸发,所得残留物用10∶1的二氯甲烷/甲醇洗脱的硅胶柱色谱纯化,然后从苯-n-己烷重结晶得出0.99克本标题名称的化合物,呈无色晶体状。熔点为50-53℃,产率61.4%。
对C29H38O8的分析(%),计算值(实测值):C,67.69(67.76);H,7.44(7.40)。
实例6-8
由如同实例5相同过程制备的实例6-8中的其他那些新化合物列于表1。
表1
试样 R m n 产率(%) 熔点(℃) 分析(%) 计算值/
实测值
6 H 2 3 69.8 86-88 C:67.18 H:7.25
66.90 7.27
7 H 3 4 87.9 62-64 C:68.16 H:7.63
68.21 7.65
8 H 4 3 72.2 47 48 C:68.16 H:7.63
68.00 7.58
试验1
豚鼠的支气管收缩的抑制
以30毫克/公斤,腹腔内(i.p.)戊基巴比妥钠麻醉重量约为450克的雄性Hartley豚鼠,在人工通气下,用Konzett-Rossler(J,Harvey,et al,J.Pharmacol.Method,9,147-155,1983)的改进方法测量动脉压的变化,从颈静脉进行大剂量白三烯D4注射(3微克/公斤,静脉注射(i,v.))引起支气管收缩响应。在白三烯D4注射之前,豚鼠用消炎痛(10毫克/公斤,静脉注射)和心得安(1毫克/公斤,静脉注射)处理,在白三烯D4激发前,还将悬浮在5%阿拉伯树胶溶液中的试验化合物口服给药2小时,结果如下表2所示:
表2
试样 剂量(毫克/公斤,口服) 抑制作用(%)
5 1.5 27.4
6.25 41.7
12.5 59.0
50 82.7
6 12.5 28.6
50 86.6
7 12.5 45.2
50 94.8
8 50 83.1
对比.1 12.5 -12.1
50 56.1
对比.2 50 16.9
对比物1为:[6-乙酰基-3-[3-(4-乙酰基-3-羟基-2-丙基苯氧基)-丙氧基]-2-丙基苯氧基]乙酸
对比物2为:[4-乙酰基-3-[5-(4-乙酰基-3-羟基-2-丙基苯氧基)-戊氧基]-2-丙基苯氧基]乙酸
(在日本专利公开号58-189137及相应的美国专利4,507,498中叙述的)
本发明化合物不仅对隔离豚鼠回肠和气管内的白三烯(leukot-riene)D4有拮抗作用,而且只需比对比物低的口服剂量就可抑制白三烯(leukotriene)D4引起的支气管收缩。
相应地,本发明化合物对白三烯(leukotriene)起主要作用的疾病,例如,支气管哮喘,耳过敏,鼻和胃肠道的过敏,荨麻疹,心血管紊乱等等的疗效是有用的。
Claims (6)
1、以下述一般式(Ⅰ)表示的苯氧基烷基羧衍生物
(式中R1表示一个氢原子,甲基或乙基,m为2,3或4,n为3或4);以及它们的碱金属盐和水合物。
5、以一般式(Ⅰ)表示的化合物的制备方法,(式中R1表示权项1中的氢原子);以及它们的碱金属盐和水合物,本方法包括由一般式(Ⅰa)表示的化合物(式中R2,m和n的定义同权项1和2中所述)的水解。
6、抗过敏剂包括由一般式(Ⅰ)表示的苯氧基烷基羧酸衍生物,或它们的碱金属盐和水合物作为活性组份的至少一种化合物
式中R1,m和n如权项1中所定义的。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP62226940A JPH0819041B2 (ja) | 1987-09-10 | 1987-09-10 | フェノキシアルキルカルボン酸誘導体及びその製造法 |
JP226940/87 | 1987-09-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1032003A true CN1032003A (zh) | 1989-03-29 |
CN1025185C CN1025185C (zh) | 1994-06-29 |
Family
ID=16852993
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN88106646A Expired - Fee Related CN1025185C (zh) | 1987-09-10 | 1988-09-10 | 苯氧基烷基羧酸衍生物及其制备方法 |
Country Status (10)
Country | Link |
---|---|
US (1) | US5023364A (zh) |
EP (1) | EP0306959B1 (zh) |
JP (1) | JPH0819041B2 (zh) |
KR (1) | KR960000037B1 (zh) |
CN (1) | CN1025185C (zh) |
AU (1) | AU608647B2 (zh) |
CA (1) | CA1327601C (zh) |
DE (1) | DE3867392D1 (zh) |
ES (1) | ES2038260T3 (zh) |
HU (1) | HU198899B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4985585A (en) | 1988-03-07 | 1991-01-15 | Kyorin Pharmaceutical Co., Ltd. | Phenoxyalkylcarboxylic acid derivatives and process for their preparations |
US5290812A (en) * | 1991-01-18 | 1994-03-01 | Kyorin Pharmaceutical Co., Ltd. | Phenoxyalkylcarboxylic acid derivatives and process of preparing the same |
DE4228201A1 (de) * | 1992-08-25 | 1994-03-03 | Schering Ag | Neue Leukotrien-B¶4¶-Antagonisten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4507498A (en) * | 1982-04-09 | 1985-03-26 | Hoffmann-La Roche Inc. | Phenoxycarboxylic acids |
US4782176A (en) * | 1983-01-24 | 1988-11-01 | Hoffmann-La Roche Inc. | Phenoxycarboxylic acids |
US4550190A (en) * | 1983-03-21 | 1985-10-29 | Hoffmann-La Roche Inc. | Naphthalenyloxy carboxylic acids |
PT85110A (en) * | 1986-06-23 | 1987-07-01 | Merck Frosst Canada Inc | Process for preparing benzenealkanoic acid derivatives useful as leukotriene antagonists |
-
1987
- 1987-09-10 JP JP62226940A patent/JPH0819041B2/ja not_active Expired - Lifetime
-
1988
- 1988-09-06 AU AU21903/88A patent/AU608647B2/en not_active Ceased
- 1988-09-08 ES ES198888114706T patent/ES2038260T3/es not_active Expired - Lifetime
- 1988-09-08 DE DE8888114706T patent/DE3867392D1/de not_active Expired - Lifetime
- 1988-09-08 EP EP88114706A patent/EP0306959B1/en not_active Expired - Lifetime
- 1988-09-08 KR KR1019880011571A patent/KR960000037B1/ko not_active IP Right Cessation
- 1988-09-09 CA CA000577020A patent/CA1327601C/en not_active Expired - Fee Related
- 1988-09-09 HU HU884662A patent/HU198899B/hu not_active IP Right Cessation
- 1988-09-10 CN CN88106646A patent/CN1025185C/zh not_active Expired - Fee Related
-
1989
- 1989-03-17 US US07/325,007 patent/US5023364A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA1327601C (en) | 1994-03-08 |
HUT47521A (en) | 1989-03-28 |
JPH0819041B2 (ja) | 1996-02-28 |
US5023364A (en) | 1991-06-11 |
CN1025185C (zh) | 1994-06-29 |
DE3867392D1 (de) | 1992-02-13 |
HU198899B (en) | 1989-12-28 |
ES2038260T3 (es) | 1993-07-16 |
EP0306959B1 (en) | 1992-01-02 |
EP0306959A1 (en) | 1989-03-15 |
JPS6470434A (en) | 1989-03-15 |
KR890005027A (ko) | 1989-05-11 |
AU608647B2 (en) | 1991-04-11 |
KR960000037B1 (ko) | 1996-01-03 |
AU2190388A (en) | 1989-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1028104C (zh) | 制备喹诺酮衍生物的方法 | |
CN101048376A (zh) | 二氢吲哚化合物及其生产方法 | |
CN1027507C (zh) | 新的磺酰化合物的制备方法 | |
CN1217720A (zh) | 苯并呋喃基衍生物及其应用 | |
CN1019491B (zh) | 用作治疗剂的新的噻吩并吡啶酮类的制备方法 | |
CN1478075A (zh) | 化学方法和新中间体 | |
CN1025185C (zh) | 苯氧基烷基羧酸衍生物及其制备方法 | |
CN1035828A (zh) | 苯并间二氧杂环戊烯衍生物及其制备方法 | |
CN1029965C (zh) | 具有氨基噻唑(亚氨基氧基乙酸)乙酸侧链的β-内酰胺的制备方法 | |
CN1518540A (zh) | 4-[4-[4-(羟基二苯基甲基)-1-哌啶基]-1-羟基丁基]-α,α-二甲基苯乙酸和其盐酸盐的新型结晶形式 | |
CN1413215A (zh) | 吡唑并哒嗪衍生物的制备方法 | |
CN1063487A (zh) | 苯氧基烷基羧酸衍生物及其制备方法 | |
CN1087337A (zh) | 取代的喹啉-2-基甲氧基苯乙酸衍生物 | |
CN1106009A (zh) | 咪唑并吡啶类衍生物的制备方法 | |
CN1014787B (zh) | 苯氧基乙酸衍生物的制备方法 | |
CN1105105C (zh) | 制备作为杀虫剂中间体2-(吡啶-2-基氧基甲基)苯乙酸酯类化合物的方法 | |
CN1258510C (zh) | 环丁酮衍生物的制备方法 | |
WO2002012221A1 (fr) | Procede de resolution optique de l'acide (±)-6-hydroxy-2,5,7,8,-tetramethyle de coumarone-2-carboxylique | |
CN1025191C (zh) | 苯并咪唑衍生物的制备方法 | |
CN1062549C (zh) | 烯丙基醌衍生物的制备方法 | |
CN1019196B (zh) | 2-噻唑烷酮类衍生物的制备方法 | |
JPH0374384A (ja) | 3r‐(3‐カルボキシベンジル)‐6‐(5‐フルオロ‐2‐ベンゾチアゾリル)メトキシ‐4r‐クロマノールの光学分割方法 | |
CN1026586C (zh) | 新的噻唑烷酮衍生物制备方法 | |
CN1235881C (zh) | 制备氟代喹诺酮羧酸的改进方法 | |
CN1094403A (zh) | 4-杂环基取代的二氢吡啶 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C15 | Extension of patent right duration from 15 to 20 years for appl. with date before 31.12.1992 and still valid on 11.12.2001 (patent law change 1993) | ||
OR01 | Other related matters | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |